95 related articles for article (PubMed ID: 32773766)
1. Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts.
Zhang P; Kovtun IV
J Vis Exp; 2020 Jul; (161):. PubMed ID: 32773766
[TBL] [Abstract][Full Text] [Related]
2. Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy.
Harris FR; Zhang P; Yang L; Hou X; Leventakos K; Weroha SJ; Vasmatzis G; Kovtun IV
Mol Oncol; 2019 Feb; 13(2):132-152. PubMed ID: 30499260
[TBL] [Abstract][Full Text] [Related]
3. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.
Roscilli G; De Vitis C; Ferrara FF; Noto A; Cherubini E; Ricci A; Mariotta S; Giarnieri E; Giovagnoli MR; Torrisi MR; Bergantino F; Costantini S; Fenizia F; Lambiase M; Aurisicchio L; Normanno N; Ciliberto G; Mancini R
J Transl Med; 2016 Feb; 14():61. PubMed ID: 26928703
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
Jäger W; Xue H; Hayashi T; Janssen C; Awrey S; Wyatt AW; Anderson S; Moskalev I; Haegert A; Alshalalfa M; Erho N; Davicioni E; Fazli L; Li E; Collins C; Wang Y; Black PC
Oncotarget; 2015 Aug; 6(25):21522-32. PubMed ID: 26041878
[TBL] [Abstract][Full Text] [Related]
5. Personalized treatment based on mini patient-derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma.
Zhao P; Chen H; Wen D; Mou S; Zhang F; Zheng S
Cancer Commun (Lond); 2018 Aug; 38(1):54. PubMed ID: 30139386
[TBL] [Abstract][Full Text] [Related]
6. Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.
Liu JF; Palakurthi S; Zeng Q; Zhou S; Ivanova E; Huang W; Zervantonakis IK; Selfors LM; Shen Y; Pritchard CC; Zheng M; Adleff V; Papp E; Piao H; Novak M; Fotheringham S; Wulf GM; English J; Kirschmeier PT; Velculescu VE; Paweletz C; Mills GB; Livingston DM; Brugge JS; Matulonis UA; Drapkin R
Clin Cancer Res; 2017 Mar; 23(5):1263-1273. PubMed ID: 27573169
[No Abstract] [Full Text] [Related]
7. Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
Ricci F; Guffanti F; Damia G; Broggini M
Mol Cancer; 2017 May; 16(1):97. PubMed ID: 28558767
[TBL] [Abstract][Full Text] [Related]
8. Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis.
Guan Z; Lan H; Chen X; Jiang X; Wang X; Jin K
Mol Med Rep; 2017 Oct; 16(4):4784-4790. PubMed ID: 28849200
[TBL] [Abstract][Full Text] [Related]
9. From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models.
Capasso M; Brignole C; Lasorsa VA; Bensa V; Cantalupo S; Sebastiani E; Quattrone A; Ciampi E; Avitabile M; Sementa AR; Mazzocco K; Cafferata B; Gaggero G; Vellone VG; Cilli M; Calarco E; Giusto E; Perri P; Aveic S; Fruci D; Tondo A; Luksch R; Mura R; Rabusin M; De Leonardis F; Cellini M; Coccia P; Iolascon A; Corrias MV; Conte M; Garaventa A; Amoroso L; Ponzoni M; Pastorino F
J Transl Med; 2024 Feb; 22(1):151. PubMed ID: 38351008
[TBL] [Abstract][Full Text] [Related]
10. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries.
Veeranki OL; Tong Z; Mejia A; Verma A; Katkhuda R; Bassett R; Kim TB; Wang J; Lang W; Mino B; Solis L; Kingsley C; Norton W; Tailor R; Wu JY; Krishnan S; Lin SH; Blum M; Hofstetter W; Ajani J; Kopetz S; Maru D
Dis Model Mech; 2019 Dec; 12(12):. PubMed ID: 31732509
[TBL] [Abstract][Full Text] [Related]
11. Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.
Wei L; Chintala S; Ciamporcero E; Ramakrishnan S; Elbanna M; Wang J; Hu Q; Glenn ST; Murakami M; Liu L; Gomez EC; Sun Y; Conroy J; Miles KM; Malathi K; Ramaiah S; Anbarasu A; Woloszynska-Read A; Johnson CS; Conroy J; Liu S; Morrison CD; Pili R
Oncotarget; 2016 Nov; 7(47):76374-76389. PubMed ID: 27823983
[TBL] [Abstract][Full Text] [Related]
12. Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer.
Tsoli M; Wadham C; Pinese M; Failes T; Joshi S; Mould E; Yin JX; Gayevskiy V; Kumar A; Kaplan W; Ekert PG; Saletta F; Franshaw L; Liu J; Gifford A; Weber MA; Rodriguez M; Cohn RJ; Arndt G; Tyrrell V; Haber M; Trahair T; Marshall GM; McDonald K; Cowley MJ; Ziegler DS
Cancer Biol Ther; 2018; 19(12):1078-1087. PubMed ID: 30299205
[TBL] [Abstract][Full Text] [Related]
13. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy.
Wallbillich JJ; Forde B; Havrilesky LJ; Cohn DE
Gynecol Oncol; 2016 Jul; 142(1):144-149. PubMed ID: 27106017
[TBL] [Abstract][Full Text] [Related]
14. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
15. Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification.
Castven D; Becker D; Czauderna C; Wilhelm D; Andersen JB; Strand S; Hartmann M; Heilmann-Heimbach S; Roth W; Hartmann N; Straub BK; Mahn FL; Franck S; Pereira S; Haupts A; Vogel A; Wörns MA; Weinmann A; Heinrich S; Lang H; Thorgeirsson SS; Galle PR; Marquardt JU
Int J Cancer; 2019 Jun; 144(11):2782-2794. PubMed ID: 30485423
[TBL] [Abstract][Full Text] [Related]
16. The emerging clinical relevance of genomics in cancer medicine.
Berger MF; Mardis ER
Nat Rev Clin Oncol; 2018 Jun; 15(6):353-365. PubMed ID: 29599476
[TBL] [Abstract][Full Text] [Related]
17. Personalized genomic analyses for cancer mutation discovery and interpretation.
Jones S; Anagnostou V; Lytle K; Parpart-Li S; Nesselbush M; Riley DR; Shukla M; Chesnick B; Kadan M; Papp E; Galens KG; Murphy D; Zhang T; Kann L; Sausen M; Angiuoli SV; Diaz LA; Velculescu VE
Sci Transl Med; 2015 Apr; 7(283):283ra53. PubMed ID: 25877891
[TBL] [Abstract][Full Text] [Related]
18. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma.
Shah RH; Scott SN; Brannon AR; Levine DA; Lin O; Berger MF
Cancer Cytopathol; 2015 May; 123(5):289-97. PubMed ID: 25655233
[TBL] [Abstract][Full Text] [Related]
20. Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis.
Wang J; Xing B; Liu W; Li J; Wang X; Li J; Yang J; Ji C; Li Z; Dong B; Gao J; Shen L
Theranostics; 2019; 9(12):3485-3500. PubMed ID: 31281492
[No Abstract] [Full Text] [Related]
[Next] [New Search]